Actively Recruiting
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
Led by Ethris GmbH · Updated on 2025-08-11
50
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
Sponsors
E
Ethris GmbH
Lead Sponsor
V
VirTus Respiratory Research Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
CONDITIONS
Official Title
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give signed informed consent and comply with study requirements
- Aged 18 to 65 years at time of consent
- Clinical asthma diagnosis with >12% reversibility after short acting beta 2 agonist or PC20 methacholine challenge <8 mg/mL
- Stable asthma maintenance on inhaled glucocorticosteroids or ICS plus long acting beta 2 agonist for at least 3 months
- Clinically stable with no asthma exacerbations within 3 months prior to dosing
- Negative serology test for rhinovirus A16
- Agree to use contraception methods if applicable
You will not qualify if you...
- Any cold symptoms such as sore throat, sneezing, runny nose, malaise, nasal obstruction, or cough within the last month
- Current allergic rhinitis, rhinosinusitis, or nasal polyps
- History or current diagnosis of chronic obstructive pulmonary disease, emphysema, cystic fibrosis, or bronchiectasis
- Any other active or chronic disease that may increase risk or affect study results, including history of emergency room visits or hospital admissions for common cold
- Current smoker or vaper, or ex-smoker who stopped within the last 12 months or has a smoking history over 5 years; current vapers may participate if willing to stop before baseline
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Virtus Respiratory Research Ltd and Imperial College Healthcare NHS Trust
London, United Kingdom
Actively Recruiting
Research Team
D
Dr. Philipp Schreppel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here